Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05564936 · ClinicalTrials.gov registry record · NA

The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis

A NA study of Myasthenia Gravis, sponsored by Ad scientiam.

Recruiting
Registry status
NA
Development phase
144
Enrollment target
19
Study locations

NCT05564936: Recruiting NA study of Myasthenia Gravis, sponsored by Ad scientiam.

NCT05564936 is a NA study of Myasthenia Gravis that is actively recruiting participants, run by Ad scientiam. The registered enrollment target is 144 participants, below the 187-participant average among 32 other Myasthenia Gravis trials with a reported enrollment target (23% lower). The trial reports 19 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05564936, a NA study of Myasthenia Gravis, is actively recruiting participants, sponsored by Ad scientiam.

RECRUITING
Registry status
NA
Development phase
144 participants
Enrollment target
19
Study locations

Study Summary

ME\&MG is a standalone software (digital solution) running on patients smartphones, connected to a web portal for physicians. It is intended to be used as an unsupervised digital self-assessment tool for the monitoring of disabilities in patients living with MG. ME\&MG contains digital active tests for the assessment of ptosis, breathing, dysarthria, upper- and lower-limb (arms and legs) weakness, treatment follow-up, and validated e-questionnaires related to daily activities, pain, fatigue, sleep, and depression disorders. The objectives of this study are to validate the accuracy, reliability and reproducibility of the unsupervised at-home self-assessment of symptoms on the patient's smartphone with ME\&MG versus the standard in-clinic testing, as well as to evaluate the safety of the solution, its usability and satisfaction.

Primary Outcome

Pearson correlation coefficient will be used to assess the relationship between digital tests versus standard tests

Conditions Studied

Myasthenia Gravis

Interventions

  • DEVICE ME&MG mobile application

Study Locations (19)

Other

  • Hôpital Raymond Poincaré - Garches
  • CHU Grenoble - Grenoble
  • Hôpital Salengro - Lille
  • CHRU Nancy - Nancy
  • CHU Nantes - Nantes
  • Pitié-Salpêtrière - Paris
  • CHU de Strasbourg - Hôpital de Hautepierre - Strasbourg
  • CHU Toulouse - Toulouse

Indiana

  • HealthParterns Institute - Bloomington
  • Indiana University Health - Indianapolis

Tennessee

  • The University of Tennessee Medical Center - Knoxville
  • Vanderbilt Health - Nashville

Colorado

  • University of Colorado Denver - Aurora

Florida

  • University of Florida Health - Jacksonville

Kentucky

  • University of Kentucky - Lexington

New York

  • Neurological Associates of Long Island, P.C. - Lake Success

North Carolina

  • Duke University - Durham

Trial Details

FieldValue
Enrollment Target 144 participants
Start Date 2024-01-24
Est. Completion 2026-09-24
Phase NA
Ad scientiam

5 total trials

What NCT05564936 shows while recruiting

NCT05564936 is an interventional study that assigns participants to a tested intervention. The registered 144 participants enrollment target is mid-sized for trials with a published cap, below the 187-participant average among 32 other Myasthenia Gravis trials with a reported enrollment target (23% lower).

The record links to 1 condition, with Myasthenia Gravis appearing as the primary indexed condition, and to 1 intervention - of which ME&MG mobile application is the first listed.

NCT05564936 lists 19 locations in 10 states (Other, Indiana, Tennessee).

Frequently Asked Questions

What is clinical trial NCT05564936 about?

NCT05564936 is a clinical study titled "The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis". ME\&MG is a standalone software (digital solution) running on patients smartphones, connected to a web portal for physicians. It is intended to be used as an unsupervised digital self-assessment tool for the monitoring of disabilities in patients living with MG. ME\&MG contains digital active tests...

What is the current status of trial NCT05564936?

This trial is currently recruiting. It is a NA study. The enrollment target is 144 participants. The study started on 2024-01-24. Estimated completion is 2026-09-24.

What conditions does trial NCT05564936 study?

This clinical trial studies the following conditions: Myasthenia Gravis.

What interventions are being tested in trial NCT05564936?

The interventions under investigation include: ME&MG mobile application (DEVICE).

Who is sponsoring clinical trial NCT05564936?

This trial is sponsored by Ad scientiam, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05564936 being conducted?

This trial has 19 study locations across Colorado, Florida, Indiana, Kentucky, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Myasthenia Gravis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05564936's enrollment target sits among peer trials

144 11th of 32 higher than 22 of 32 other Myasthenia Gravis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Myasthenia Gravis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01861106 · 144 participants · Phase 2

    Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations

  • NCT03482245 · 144 participants · NA

    The Role of Circadian Clock Proteins in Innate and Adaptive Immunity

  • NCT03504683 · 144 participants · NA

    MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors in Adults With Prediabetes

  • NCT03905603 · 144 participants · Early Phase 1

    Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05564936

Source: ClinicalTrials.gov NCT05564936, the US trial registry maintained by the National Library of Medicine. NCT05564936 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.